Maxim Group Initiates Coverage On Avenue Therapeutics with Buy Rating, Announces Price Target of $0.75
Portfolio Pulse from Benzinga Newsdesk
Maxim Group analyst Jason McCarthy has initiated coverage on Avenue Therapeutics (NASDAQ:ATXI) with a Buy rating and set a price target of $0.75.

December 11, 2023 | 2:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Avenue Therapeutics received a Buy rating from Maxim Group with a price target of $0.75, indicating a positive outlook from the analyst.
Analyst ratings, especially initiations of coverage with a Buy rating, can have a significant positive impact on a company's stock price in the short term. The price target of $0.75 suggests a level of confidence in the company's potential to grow, which may influence investor sentiment and lead to an increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100